Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
4.900
+0.170 (3.59%)
At close: Dec 19, 2025, 4:00 PM EST
5.11
+0.21 (4.29%)
After-hours: Dec 19, 2025, 7:55 PM EST
Alvotech Revenue
Alvotech had revenue of $113.86M in the quarter ending September 30, 2025, with 10.56% growth. This brings the company's revenue in the last twelve months to $573.35M, up 45.55% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$573.35M
Revenue Growth
+45.55%
P/S Ratio
2.47
Revenue / Employee
$566,551
Employees
1,012
Market Cap
1.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALVO News
- 3 days ago - Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman - PRNewsWire
- 3 days ago - Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering - GlobeNewsWire
- 4 days ago - Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript - Seeking Alpha
- 26 days ago - Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area - GlobeNewsWire
- 4 weeks ago - Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 5 weeks ago - Alvotech (ALVO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update - GlobeNewsWire
- 5 weeks ago - Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO) - GlobeNewsWire